Modern imaging making a real difference
Rebecca Sinnott-Devaux, Postdoctoral Associate, University at Albany, SUNY, New York
In Dr. Herschkowitz’s lab at the Cancer Research Center at the University at Albany, I am focused on the study of long noncoding RNAs and how they function in breast cancer progression. Over the past 30 years, advances in imaging technology and increased emphasis on early detection have led to a dramatic increase in the diagnosis of ductal carcinoma in situ (DCIS), a precancerous growth in the breast. Although only 40% of diagnosed DCIS cases are predicted to progress into breast cancer, we currently cannot distinguish between those DCIS cases that would remain harmless, and those that require immediate attention. Therefore, a DCIS diagnosis results in a cancer diagnosis, surgery, potentially radiation therapy, and potentially hormone therapy as well. This has created a current state of overdiagnosis and overtreatment, impacting tens of thousands of women every year. The only way to truly combat overtreatment is to gain a better understanding of the biology underlying breast cancer progression to better inform patient treatment, or nontreatment, options. Long noncoding RNAs (lncRNAs) are relatively new players in both normal biology and in impacting disease. Our studies focus on the expression of lncRNAs that are misregulated in breast cancer progression. Recently, we purchased the InvitrogenTM iBrightTM CL1000 Imaging System from Thermo Fisher Scientific. This instrument was critical to our lab environment as it not only replaced older, less efficient technology, but also combined white light, UV, and chemiluminescence imaging in one unit. For my studies, this instrument has been wonderful for developing southern and western blots to look at RNA:protein interactions, but in reality the entire department uses this instrument, taking advantage of its versatility. It has been a great addition to our platform.
The iBright CL1000 and FL1000 Imaging Systems are high-performance instruments that help enhance the western blot and gel imaging experience through advanced automated features and a streamlined, easy-to-use interface. Both models feature chemiluminescent blot, nucleic acid gel, and protein gel imaging modes. The FL1000 model also offers fluorescent blot imaging capability. Complete with a powerful 9.1 megapixel camera, proprietary InvitrogenTM Smart ExposureTM acquisition technology, and Thermo Fisher Cloud connectivity, the iBright systems enable customers to capture and analyse western blots faster and easier than before.
“We continue on the path of developing innovative products that streamline and modernise western blotting,” said Paul Haney, senior product manager at Thermo Fisher Scientific. “With the iBright Imaging Systems, we aim to improve the convenience, speed, and quality of western blot experimentation and circumvent the limitations associated with the capture of western blot images using x-ray film. Our iBright FL1000 model is designed to work seamlessly with our Thermo ScientificTM SuperSignalTM chemiluminescent substrates or our InvitrogenTM Alexa FluorTM Plus reagents for maximum multiplexing abilities. To put it simply, the iBright FL1000 model is the most advanced western blot imaging system available in both design and capability.”
To learn more, or to request a live demo to see for yourself how the iBright Imaging Systems can streamline your research, go to thermofisher.com/ibright
